Our top pick for
XBiotech Inc is a biotechnology business based in the US. XBiotech shares (XBIT) are listed on the NASDAQ and all prices are listed in US Dollars. XBiotech employs 78 staff and has a trailing 12-month revenue of around USD$28.2 million.
Since the stock market crash in March caused by coronavirus, XBiotech's share price has had significant positive movement.
Its last market close was USD$19.41, which is 27.51% up on its pre-crash value of USD$14.07 and 122.59% up on the lowest point reached during the March crash when the shares fell as low as USD$8.72.
If you had bought USD$1,000 worth of XBiotech shares at the start of February 2020, those shares would have been worth USD$446.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$892.86.
|Latest market close||USD$19.41|
|52-week range||USD$8.72 - USD$26.4|
|50-day moving average||USD$19.3186|
|200-day moving average||USD$16.0837|
|Wall St. target price||USD$18|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$15.243|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-15)||N/A|
|1 month (2020-10-22)||N/A|
|3 months (2020-08-22)||N/A|
|6 months (2020-05-22)||N/A|
|1 year (2019-11-22)||N/A|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
Valuing XBiotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XBiotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
XBiotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, XBiotech shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$28.2 million|
|Gross profit TTM||USD$0|
|Return on assets TTM||-8.16%|
|Return on equity TTM||326.16%|
|Market capitalisation||USD$538.3 million|
TTM: trailing 12 months
There are currently 1.8 million XBiotech shares held short by investors – that's known as XBiotech's "short interest". This figure is 11.6% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting XBiotech shares can be evaluated.
XBiotech's "short interest ratio" (SIR) is the quantity of XBiotech shares currently shorted divided by the average quantity of XBiotech shares traded daily (recently around 168305.23311132). XBiotech's SIR currently stands at 10.51. In other words for every 100,000 XBiotech shares traded daily on the market, roughly 10510 shares are currently held short.
However XBiotech's short interest can also be evaluated against the total number of XBiotech shares, or, against the total number of tradable XBiotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XBiotech's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 XBiotech shares in existence, roughly 60 shares are currently held short) or 0.1239% of the tradable shares (for every 100,000 tradable XBiotech shares, roughly 124 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against XBiotech.
Find out more about how you can short XBiotech stock.
We're not expecting XBiotech to pay a dividend over the next 12 months.
Over the last 12 months, XBiotech's shares have ranged in value from as little as $8.72 up to $26.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XBiotech's is 1.5019. This would suggest that XBiotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.